Ralliant Corporation $RAL Shares Bought by Victory Capital Management Inc.

Key Points

• Victory Capital Management increased its stake in Ralliant by 1,726.7%, buying an additional 825,960 shares for a total of 873,794 shares (about 0.77% of the company) valued at roughly $38.2 million.
• Analysts are mixed: Ralliant carries a consensus rating of Hold with a consensus price target of $50.50, even as firms like Barclays, Morgan Stanley and RBC recently revised their targets.
• Ralliant topped quarterly EPS ($0.69 vs. $0.67) and revenue estimates, provided Q1 and FY2026 guidance, and declared a quarterly dividend of $0.05 (annualized yield ~0.4%).

Victory Capital Management Inc. lifted its holdings in shares of Ralliant Corporation (NYSE:RAL - Free Report) by 1,726.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 873,794 shares of the company's stock after purchasing an additional 825,960 shares during the quarter. Victory Capital Management Inc. owned about 0.77% of Ralliant worth $38,211,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in RAL. Westfuller Advisors LLC acquired a new position in shares of Ralliant in the third quarter valued at approximately $26,000. Manchester Capital Management LLC acquired a new stake in Ralliant during the 2nd quarter worth approximately $29,000. UMB Bank n.a. acquired a new stake in Ralliant during the 3rd quarter worth approximately $29,000. Webster Bank N. A. purchased a new position in Ralliant in the 3rd quarter valued at approximately $31,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Ralliant in the third quarter worth $34,000.

Analysts Set New Price Targets

A number of analysts have recently weighed in on RAL shares. Barclays cut their price objective on Ralliant from $60.00 to $52.00 and set an "overweight" rating on the stock in a research report on Monday, February 9th. Morgan Stanley reiterated an "overweight" rating and issued a $45.00 target price on shares of Ralliant in a report on Friday, February 6th. Weiss Ratings cut Ralliant from a "hold (c)" rating to a "sell (d)" rating in a research note on Thursday, February 5th. Royal Bank Of Canada reduced their price target on Ralliant from $52.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 6th. Finally, Vertical Research upgraded Ralliant from a "hold" rating to a "buy" rating and set a $45.00 price objective for the company in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Ralliant presently has a consensus rating of "Hold" and a consensus price target of $50.50.

Insider Activity at Ralliant

In other Ralliant news, Director Kate Mitchell acquired 2,350 shares of the stock in a transaction dated Tuesday, February 10th. The stock was acquired at an average cost of $42.48 per share, with a total value of $99,828.00. Following the transaction, the director owned 8,411 shares in the company, valued at $357,299.28. The trade was a 38.77% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anelise Angelino Sacks acquired 2,000 shares of the company's stock in a transaction dated Monday, February 9th. The stock was acquired at an average price of $41.25 per share, for a total transaction of $82,500.00. Following the acquisition, the director owned 5,403 shares in the company, valued at approximately $222,873.75. The trade was a 58.77% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 8,145 shares of company stock worth $332,233 over the last three months.

Ralliant Trading Down 3.5%

Shares of NYSE:RAL opened at $44.74 on Friday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $57.02. The company's 50 day moving average is $48.94 and its two-hundred day moving average is $46.66. The company has a market cap of $5.00 billion and a PE ratio of 22.83. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analysts' expectations of $543.04 million. The firm's quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant's payout ratio is 10.20%.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.